Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLO-Trial: Precise Neoadjuvant Chemoresection of Low-grade NMIBC
NCT06227065Phase 2Not yet recruiting
- Sponsor
- Spitalzentrum Biel
- Start
- Dec 2026
- Primary completion
- Nov 2030
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of epirubicin, mitomycin c, gemcitabine, docetaxel in non-muscle-invasive bladder cancer (NMIBC), sponsored by Spitalzentrum Biel. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
epirubicinmitomycin cgemcitabinedocetaxel
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06227065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06227065.